Physician profile
Burton Jared Tabaac
NPI 1295154219
$287,285.46
in general payments reported to CMS, 2019-2025
50 companies · $178K in 2025
The $178K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $126 · 2021: $345 · 2022: $13K · 2023: $28K · 2024: $68K · 2025: $178K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $247K · Food and Beverage: $14K · Travel and Lodging: $11K · Consulting Fee: $1,525 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $247,405.00 |
| Food and Beverage | $13,772.31 |
| Travel and Lodging | $11,285.05 |
| Consulting Fee | $1,525.00 |
| Education | $109.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $90,413.87 | 2023-2025 | Kisunla, Amyvid, Emgality |
| Otsuka America Pharmaceutical, INC. | $73,163.47 | 2024-2025 | Rexulti |
| Abbvie INC. | $50,942.17 | 2022-2025 | Ubrelvy, Qulipta, Botox |
| Astrazeneca Pharmaceuticals Lp | $41,083.02 | 2022-2024 | Andexxa |
| Pfizer INC. | $24,175.96 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $864.89 | 2022-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $618.33 | 2023-2025 | Zilbrysq, Fintepla, Rystiggo |
| Lundbeck LLC | $496.93 | 2022-2025 | Vyepti, Rexulti |
| Argenx US, INC. | $495.57 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Biogen, INC. | $440.09 | 2022-2025 | Vumerity, Tysabri, Spinraza |
| Impel Pharmaceuticals INC. | $437.62 | 2022-2023 | Trudhesa |
| Alexion Pharmaceuticals, INC. | $388.13 | 2021-2025 | Ultomiris |
| Tanabe Pharma America, INC. | $307.82 | 2023-2025 | Radicava |
| Celgene Corporation | $279.35 | 2022-2025 | Zeposia |
| Genentech USA, INC. | $270.75 | 2023-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $240.75 | 2020-2021 | |
| Harmony Biosciences LLC | $238.20 | 2023-2025 | Wakix |
| Emd Serono, INC. | $198.12 | 2022-2025 | Mavenclad |
| Biohaven Pharmaceutical Holding Company Ltd. | $186.89 | 2022 | |
| Scilex Pharmaceuticals INC. | $182.82 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $129.47 | 2023-2025 | Rytary, Crexont |
| Amgen INC. | $128.98 | 2022-2025 | Repatha, Aimovig |
| Eisai INC. | $127.49 | 2025 | |
| Axsome Therapeutics, INC. | $118.37 | 2025 | Symbravo |
| Acorda Therapeutics, INC | $111.75 | 2023-2024 | Inbrija |
| Cala Health, INC. | $107.38 | 2023-2025 | Cala Kiq, Cala Kiq, Cala Trio |
| Ceribell, INC. | $104.46 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $98.28 | 2022-2025 | Austedo Xr |
| Octapharma USA, INC. | $85.12 | 2023-2024 | Panzyga, Octagam Immune Globulin (Human) |
| Takeda Pharmaceuticals U.S.A., INC. | $70.94 | 2024-2025 | Hyqvia |
| Kyowa Kirin, INC. | $66.66 | 2024 | Nourianz |
| Banner Life Sciences, LLC | $63.62 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $62.82 | 2023 | Dupixent |
| Upsher-Smith Laboratories LLC | $57.79 | 2023 | |
| Neurelis, INC. | $47.74 | 2024-2025 | Valtoco |
| Insightec,INC | $47.16 | 2025 | Exablate |
| Merz Pharmaceuticals, LLC | $44.93 | 2025 | Xeomin |
| Ge Healthcare | $43.84 | 2022-2025 | |
| Mylan Specialty L.P. | $42.97 | 2024 | |
| Novartis Pharmaceuticals Corporation | $39.49 | 2025 | |
| Acadia Pharmaceuticals INC | $35.97 | 2023-2025 | Nuplazid |
| Mdd US Operations, LLC | $35.80 | 2024-2025 | Gocovri, Qelbree |
| Sumitomo Pharma America, INC. | $31.64 | 2023 | Aptiom |
| Ani Pharmaceuticals, INC. | $30.47 | 2025 | Purified Cortrophin Gel |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $26.35 | 2023 | Rexulti |
| Itf Therapeutics LLC | $23.90 | 2025 | |
| Supernus Pharmaceuticals, INC. | $23.81 | 2023 | |
| Averitas Pharma INC. | $18.18 | 2023 | Qutenza |
| Janssen Pharmaceuticals, INC | $18.07 | 2024 | Spravato |
| Actelion Pharmaceuticals US, INC. | $17.26 | 2023 | Opsumit, Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Burton Tabaac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.